1. Home
  2. LC vs GLPG Comparison

LC vs GLPG Comparison

Compare LC & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LendingClub Corporation

LC

LendingClub Corporation

HOLD

Current Price

$15.96

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$34.44

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LC
GLPG
Founded
2006
1999
Country
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LC
GLPG
Price
$15.96
$34.44
Analyst Decision
Buy
Hold
Analyst Count
6
3
Target Price
$22.67
$31.33
AVG Volume (30 Days)
2.7M
98.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.76
Revenue Next Year
$15.91
$0.49
P/E Ratio
$13.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.90
$22.59
52 Week High
$21.67
$37.78

Technical Indicators

Market Signals
Indicator
LC
GLPG
Relative Strength Index (RSI) 39.00 58.89
Support Level $15.00 $33.39
Resistance Level $17.63 $34.22
Average True Range (ATR) 1.00 0.62
MACD -0.16 -0.05
Stochastic Oscillator 28.16 77.84

Price Performance

Historical Comparison
LC
GLPG

About LC LendingClub Corporation

LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: